Keeping Checkpoint Inhibitors in Check

Daniel V T Catenacci^{1

2}, Howard Hochster³, Samuel J Klempner⁴

Affiliations

¹ Department of Medicine-Hematology/Oncology, The University of Chicago Medical Center, Chicago, Illinois.
² Associate Editor.
³ Rutgers Cancer Institute of New Jersey, New Brunswick.
⁴ The Angeles Clinic and Research Institute, Los Angeles, California.

Free article

Comment

Daniel V T Catenacci et al. JAMA Netw Open. 2019.

Free article

. 2019 May 3;2(5):e192546.

doi: 10.1001/jamanetworkopen.2019.2546.

Daniel V T Catenacci^{1

2}, Howard Hochster³, Samuel J Klempner⁴

¹ Department of Medicine-Hematology/Oncology, The University of Chicago Medical Center, Chicago, Illinois.
² Associate Editor.
³ Rutgers Cancer Institute of New Jersey, New Brunswick.
⁴ The Angeles Clinic and Research Institute, Los Angeles, California.

No abstract available

Comment on

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
Haslam A, Prasad V. Haslam A, et al. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535. JAMA Netw Open. 2019. PMID: 31050774 Free PMC article.